German genetic diagnostics company CeGaT has been growing rapidly over the last year to accommodate increasing demand for next-generation sequencing-based diagnostic tests in Germany and beyond.

The firm's portfolio of gene panels for inherited disorders has expanded to 14 disease areas, including hereditary cancer. The number of panels, many of which it developed in collaboration with academic partners, has nearly doubled to about 120. CeGaT also has started offering diagnostic exome sequencing, mainly of parent-child trios.